
Metastasis-directed therapy (MDT) for metastatic prostate cancer (mPCa) exhibits promising outcomes, with estimated 2-year progression-free survival (PFS) of 46%, excellent local control (LC) at 97%, and low toxicity rates. While MDT allows oligorecurrent hormone-sensitive patients to defer and avoid androgen deprivation therapy (ADT)-related toxicity, its integration with systemic treatments and as part of definitive care for oligometastatic PCa holds research potential. Despite lacking randomized trials, MDT serves as an experimental approach for treatment intensification.
Like
Save
Share